Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia
Henrik Hauswald,Felix Zwicker,Nathalie Rochet,Matthias Uhl,Frank W. Hensley,Jürgen Debus,Klaus Herfarth,Marc Bischof +7 more
TL;DR: For palliation of symptomatic cutaneous manifestations of advanced cutaneous lymphoma or leukemia, total skin electron beam therapy is an efficient and well tolerated considerable treatment option.
read more
Abstract: To retrospectively access the outcome and toxicity of a total skin electron beam therapy (TSEBT) in patients with cutaneous lymphoma (CL) or leukemia. Treatment results of 25 patients (median age 63 years; 5 female, 20 male) with cutaneous manifestations of advanced and therapy-refractory CL (n = 21; T-cell lymphomas n = 18, B-cell lymphomas n = 3) stage IIB-IV or leukemia (n = 4; AML n = 2, CLL n = 1, PDC n = 1) treated between 1993 and 2010 were reviewed. All patients were symptomatic. The median total dose was 29Gy, applied in 29 fractions of median 1 Gy each. The median follow-up was 10 months. Palliation was achieved in 23 patients (92%). A clinical complete response was documented in 13 (52%) and a partial response in 10 patients (40%). The median time to skin progression was 5 months (range 1–18 months) and the actuarial one-year progression-free survival 35%. The median overall survival (OS) after the initiation of TSEBT was 10 months (range 1–46 months) and the actuarial one-year OS 45%. TSEBT related acute adverse events (grade 1 or 2) were observed in all patients during the treatment period. An acute grade 3 epitheliolysis developed in eight patients (32%). Long-term adverse events as a hyperpigmentation of the skin (grade 1 or 2) were documented in 19 patients (76%), and a hypohidrosis in seven patients (28%). For palliation of symptomatic cutaneous manifestations of advanced cutaneous lymphoma or leukemia, total skin electron beam therapy is an efficient and well tolerated considerable treatment option.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma
Khaled Elsayad,Jan Kriz,Christos Moustakis,Sergiu Scobioala,Gabriele Reinartz,Uwe Haverkamp,Normann Willich,Carsten Weishaupt,Rudolf Stadler,Cord Sunderkötter,Hans Theodor Eich +10 more
TL;DR: TSEB therapy is an efficacious treatment modality in the treatment of several forms of cutaneous T-cell lymphoma and there is a nonsignificant trend to higher and longer clinical benefit for MF and SS patients receiving conventional dose.
79
The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications
Ercole Mazzeo,Laura Rubino,Michela Buglione,Paolo Antognoni,Stefano Maria Magrini,Francesco Bertoni,M. Parmiggiani,Paola Barbieri,Filippo Bertoni +8 more
TL;DR: Evaluating the current treatment of mycosis fungoides and Sézary syndrome focusing on the role of radiotherapy (RT), its principles and indications, and the perspectives of the novel irradiation technologies finds that RT remains an option for all stages with a good cost/effectiveness ratio in a curative or palliative setting.
32
Literature review of clinical results of total skin electron irradiation (TSEBT) of mycosis fungoides in adults.
Fabio Y. Moraes,Heloisa de Andrade Carvalho,Samir Abdallah Hanna,João Luis Fernandes da Silva,Gustavo Nader Marta +4 more
TL;DR: TSEBT can be used to treat any stage of Mycosis fungoides and presents good tumor response with symptoms of relief and a palliative effect on MF, either after previous irradiation or failure of other treatment strategies.
29
Masitinib monotherapy in canine epitheliotropic lymphoma
TL;DR: In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma, but its effects are most likely not generated through the KIT receptor.
28
The effectiveness of radiotherapy for leukemia cutis.
TL;DR: A radiation dose ≤26 Gy confer a comparable CRR to high-dose regimens and appears to be an effective treatment for controlling LC progression, however, radiation doses >26 Gy were associated with a longer DOLC.
27
References
WHO-EORTC classification for cutaneous lymphomas.
Rein Willemze,Elaine S. Jaffe,Günter Burg,Lorenzo Cerroni,Emilio Berti,Steven H. Swerdlow,Elisabeth Ralfkiaer,Sergio Chimenti,José Luis Diaz-Perez,Lyn M. Duncan,Florent Grange,Nancy L. Harris,Werner Kempf,Helmut Kerl,Michael O. Kurrer,Robert Knobler,Nicola Pimpinelli,Chris Sander,Marco Santucci,Wolfram Sterry,Maarten H. Vermeer,Janine Wechsler,Sean Whittaker,Chris J.L.M. Meijer +23 more
TL;DR: The characteristic features of the different primary cutaneous lymphomas and other hematologic neoplasms frequently presenting in the skin are described, and differences with the previous classification schemes are discussed.
3.8K
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).
Elise A. Olsen,Eric C. Vonderheid,Nicola Pimpinelli,Rein Willemze,Youn H. Kim,Robert Knobler,Herschel S. Zackheim,Madeleine Duvic,Teresa Estrach,Stanford I. Lamberg,Gary S. Wood,Reinhard Dummer,Annamari Ranki,Günter Burg,Peter Heald,Mark R. Pittelkow,M.G. Bernengo,Wolfram Sterry,Liliane Laroche,Franz Trautinger,Sean Whittaker +20 more
TL;DR: These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques as pertains to mycosis fungoides and Sézary syndrome to clarify certain variables that currently impede effective interinstitution and interinvestigator communication and/or the development of standardized clinical trials in MF and SS.
1.2K
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases
TL;DR: Cutaneous lymphomas rates vary markedly by race and sex, supporting the notion that they represent distinct disease entities.
639
InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions.
Jennifer J. Turner,Lindsay M. Morton,Martha S. Linet,Christina A. Clarke,Marshall E. Kadin,Claire M. Vajdic,Alain Monnereau,Marc Maynadié,Brian C.-H. Chiu,Rafael Marcos-Gragera,Adele Seniori Costantini,James R. Cerhan,Dennis D. Weisenburger +12 more
TL;DR: The Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) now presents an update of the hierarchical classification of lymphoid neoplasms for epidemiologic research based on the 2001 WHO classification, encouraging epidemiologists to adopt the updated InterLymph hierarchical classification.
230
Related Papers (5)
Rein Willemze,Elaine S. Jaffe,Günter Burg,Lorenzo Cerroni,Emilio Berti,Steven H. Swerdlow,Elisabeth Ralfkiaer,Sergio Chimenti,José Luis Diaz-Perez,Lyn M. Duncan,Florent Grange,Nancy L. Harris,Werner Kempf,Helmut Kerl,Michael O. Kurrer,Robert Knobler,Nicola Pimpinelli,Chris Sander,Marco Santucci,Wolfram Sterry,Maarten H. Vermeer,Janine Wechsler,Sean Whittaker,Chris J.L.M. Meijer +23 more
Elise A. Olsen,Sean Whittaker,Youn H. Kim,Madeleine Duvic,H. Miles Prince,Stuart R. Lessin,Gary S. Wood,Rein Willemze,Marie-France Demierre,Nicola Pimpinelli,Maria Grazia Bernengo,Pablo L. Ortiz-Romero,Martine Bagot,Teresa Estrach,Joan Guitart,Robert Knobler,José Antonio Sanches,Keiji Iwatsuki,Makoto Sugaya,Reinhard Dummer,Mark R. Pittelkow,Richard T. Hoppe,Sareeta Parker,Larisa J. Geskin,Lauren Pinter-Brown,Michael Girardi,Guenter Burg,Annamari Ranki,Maartan Vermeer,Steven M. Horwitz,Peter Heald,Steve Rosen,Lorenzo Cerroni,B. Dréno,Eric C. Vonderheid +34 more